Adverse Drug Reactions in Therapeutic Hypothermia After Cardiac Arrest

Overview

Journal Ther Adv Drug Saf

Publisher Sage Publications

Date 2017 Apr 7

PMID 28382198

Citations 3

Authors

Robert Witcher

Amy L Dzierba

Catherine Kim

Pamela L Smithburger

Sandra L Kane-Gill

Affiliations

Soon will be listed here.

Abstract

Background: Therapeutic hypothermia (TH) improves survival and neurologic function in comatose survivors of cardiac arrest. Many medications used to support TH have altered pharmacokinetics and pharmacodynamics during this treatment. It is unknown if or at what frequency the medications used during TH cause adverse drug reactions (ADRs).

Methods: A retrospective chart review was conducted for patients admitted to an intensive care unit (ICU) after cardiac arrest and treated with TH from January 2009 to June 2012 at two urban, university-affiliated, tertiary-care medical centres. Medications commonly used during TH were screened for association with significant ADRs (grade 3 or greater per Common Terminology Criteria for Adverse Events) using three published ADR detection instruments.

Results: A total of 229 patients were included, the majority being males with median age of 62 presenting with an out-of-hospital cardiac arrest in pulseless electrical activity or asystole. The most common comorbidities were hypertension, coronary artery disease, and diabetes mellitus. There were 670 possible ADRs and 69 probable ADRs identified. Of the 670 possible ADRs, propofol, fentanyl, and acetaminophen were the most common drugs associated with ADRs. Whereas fentanyl, insulin, and propofol were the most common drugs associated with a probable ADR. Patients were managed with TH for a median of 22 hours, with 38% of patients surviving to hospital discharge.

Conclusions: Patients undergoing TH after cardiac arrest frequently experience possible adverse reactions associated with medications and the corresponding laboratory abnormalities are significant. There is a need for judicious use and close monitoring of drugs in the setting of TH until recommendations for dose adjustments are available to help prevent ADRs.

Citing Articles

Survival and neurological function in patients treated with extracorporeal membrane oxygenation and therapeutic hypothermia: a protocol for updating a systematic review.

Cheng P, Wang H, Guo L, Wang M, Xu H, Gu P BMJ Open. 2024; 14(3):e081207.

PMID: 38531575 PMC: 10966782. DOI: 10.1136/bmjopen-2023-081207.

Polypharmacy prior to in-hospital cardiac arrest among patients with cardiopulmonary diseases: A pilot study.

Attin M, Abiola S, Magu R, Rosero S, Apostolakos M, Groth C Resusc Plus. 2021; 4.

PMID: 33969325 PMC: 8104360. DOI: 10.1016/j.resplu.2020.100026.

Outcomes and Adverse Effects With Peramivir for the Treatment of Influenza H1N1 in Critically Ill Pediatric Patients.

Witcher R, Tracy J, Santos L, Chopra A J Pediatr Pharmacol Ther. 2019; 24(6):497-503.

PMID: 31719811 PMC: 6836703. DOI: 10.5863/1551-6776-24.6.497.

References

Xiao G, Guo Q, Shu M, Xie X, Deng J, Zhu Y . Safety profile and outcome of mild therapeutic hypothermia in patients following cardiac arrest: systematic review and meta-analysis. Emerg Med J. 2012; 30(2):91-100. DOI: 10.1136/emermed-2012-201120. View

Pichon N, Amiel J, Francois B, Dugard A, Etchecopar C, Vignon P . Efficacy of and tolerance to mild induced hypothermia after out-of-hospital cardiac arrest using an endovascular cooling system. Crit Care. 2007; 11(3):R71. PMC: 2206437. DOI: 10.1186/cc5956. View

Tortorici M, Kochanek P, Bies R, Poloyac S . Therapeutic hypothermia-induced pharmacokinetic alterations on CYP2E1 chlorzoxazone-mediated metabolism in a cardiac arrest rat model. Crit Care Med. 2006; 34(3):785-91. DOI: 10.1097/01.ccm.0000201899.52739.4f. View

Goh C . An approach to the evaluation and documentation of adverse drug reaction. Singapore Med J. 1989; 30(3):285-9. View

Evans R, Pestotnik S, Classen D, Bass S, Menlove R, Gardner R . Development of a computerized adverse drug event monitor. Proc Annu Symp Comput Appl Med Care. 1991; :23-7. PMC: 2247488. View

Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson T, Flegal K . Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008; 119(3):e21-181. DOI: 10.1161/CIRCULATIONAHA.108.191261. View

Tortorici M, Kochanek P, Poloyac S . Effects of hypothermia on drug disposition, metabolism, and response: A focus of hypothermia-mediated alterations on the cytochrome P450 enzyme system. Crit Care Med. 2007; 35(9):2196-204. DOI: 10.1097/01.ccm.0000281517.97507.6e. View

de Haan T, Bijleveld Y, van der Lee J, Groenendaal F, van den Broek M, Rademaker C . Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. BMC Pediatr. 2012; 12:45. PMC: 3358232. DOI: 10.1186/1471-2431-12-45. View

Nielsen N, Sunde K, Hovdenes J, Riker R, Rubertsson S, Stammet P . Adverse events and their relation to mortality in out-of-hospital cardiac arrest patients treated with therapeutic hypothermia. Crit Care Med. 2010; 39(1):57-64. DOI: 10.1097/CCM.0b013e3181fa4301. View

10.

Poloyac S . Altered drug metabolism in critically ill children: a significant source of adverse effects?. Pediatr Crit Care Med. 2012; 13(1):118-9. DOI: 10.1097/PCC.0b013e318202f5a6. View

11.

Rothschild J, Landrigan C, Cronin J, Kaushal R, Lockley S, Burdick E . The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med. 2005; 33(8):1694-700. DOI: 10.1097/01.ccm.0000171609.91035.bd. View

12.

Nielsen N, Hovdenes J, Nilsson F, Rubertsson S, Stammet P, Sunde K . Outcome, timing and adverse events in therapeutic hypothermia after out-of-hospital cardiac arrest. Acta Anaesthesiol Scand. 2009; 53(7):926-34. DOI: 10.1111/j.1399-6576.2009.02021.x. View

13.

Kane-Gill S, Visweswaran S, Saul M, Wong A, Penrod L, Handler S . Computerized detection of adverse drug reactions in the medical intensive care unit. Int J Med Inform. 2011; 80(8):570-8. PMC: 3139253. DOI: 10.1016/j.ijmedinf.2011.04.005. View

14.

Valentin A, Capuzzo M, Guidet B, Moreno R, Dolanski L, Bauer P . Patient safety in intensive care: results from the multinational Sentinel Events Evaluation (SEE) study. Intensive Care Med. 2006; 32(10):1591-8. DOI: 10.1007/s00134-006-0290-7. View

15.

Bjelland T, Klepstad P, Haugen B, Nilsen T, Dale O . Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. Drug Metab Dispos. 2012; 41(1):214-23. DOI: 10.1124/dmd.112.045567. View

16.

Kopp B, Erstad B, Allen M, Theodorou A, Priestley G . Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med. 2006; 34(2):415-25. DOI: 10.1097/01.ccm.0000198106.54306.d7. View

17.

Peberdy M, Callaway C, Neumar R, Geocadin R, Zimmerman J, Donnino M . Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S768-86. DOI: 10.1161/CIRCULATIONAHA.110.971002. View

18.

Bell S . Effect of therapeutic hypothermia on drug metabolism. Neonatal Netw. 2012; 31(1):48-51. DOI: 10.1891/0730-0832.31.1.48. View

19.

Zhou J, Poloyac S . The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol. 2011; 7(7):803-16. PMC: 3116014. DOI: 10.1517/17425255.2011.574127. View

20.

Nunnally M, Jaeschke R, Bellingan G, Lacroix J, Mourvillier B, Rodriguez-Vega G . Targeted temperature management in critical care: a report and recommendations from five professional societies. Crit Care Med. 2010; 39(5):1113-25. DOI: 10.1097/CCM.0b013e318206bab2. View